Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 126

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 126
---
, in each case if and only if:

| • |     | Aadi’s board of directors determines in good faith (after consultation with its financial advisor and                                   
 outside legal counsel) that the failure to take such actions could reasonably be expected to be inconsistent with its fiduciary duties; |

| • |     | Aadi and Aadi Sub have complied in all material respects with their obligations under the Divestiture Agreement 
 with respect to such acquisition proposal;                                                                      |

| • |     | Aadi or Aadi Sub has provided prior written notice to Kaken that Aadi’s board of directors has (1) made                                                                                                                                                
 the determination that the failure to enter into an Alternative Acquisition Agreement with respect to such Superior Proposal could reasonably be expected to be inconsistent with its fiduciary duties, (2) received a written acquisition proposal    
 that has not been withdrawn, (3) determined in good faith (after consultation with its financial advisor and outside legal counsel) that such acquisition proposal constitutes a Superior Proposal, and (4) resolved to effect an Aadi Board           
 Recommendation Change and if applicable to terminate the Divestiture Agreement, which notice will describe the basis for such Aadi Board Recommendation Change and (if applicable) termination, including the identity of the third person (other than 
 Kaken or any of its affiliates or any groups of Kaken) making such acquisition proposal, the terms of such acquisition proposal in reasonable detail (including all material terms) and copies of all relevant documents relating to such acquisition  
 proposal; and                                                                                                                                                                                                                                          |

| • |     | prior to effecting such Aadi Board Recommendation Change and (if applicable) termination, Aadi, Aadi Sub and                                                                                                                                          
 their representatives, until 5:00 p.m. Pacific time on the fourth business day following the date of delivery of such written notice (which we refer to as the “Notice Period”), (1) have negotiated with Kaken and its representatives in good       
 faith (to the extent that Kaken requests to negotiate) to make such adjustments to the terms and conditions of the Divestiture Agreement and the other transaction documents so that Aadi’s board of directors no longer determines in good faith     
 that the failure to make an Aadi Board Recommendation Change in response to such acquisition proposal could reasonably be expected to be inconsistent with its fiduciary duties, or that such acquisition proposal continues to constitute a Superior 
 Proposal, and (2) have permitted Kaken and its representatives to negotiate with Aadi and its representatives throughout such period and to make a